Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 1,001–1,100 of 1,639
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
“Patients were randomised 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks [45].”
InfluentialThe year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies
Bauersachs, J. K., de Boer, R. A., & Zieroth, S. R. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad878 · Cited by 1
Loizidis, G., & Summer, R. S. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08212-w · Cited by 1
Understanding HFpEF Through Imaging
Harada, T., Naser, J. A., Ghanbari, F., & Borlaug, B. A. (2026) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2026.05.017 · Cited by 3
Self-citationVest, A. R., & Deswal, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102715 · Cited by 1
Dons, M., Sengeløv, M., Borchsenius, J., Ottosen, C. I., Fudim, M., Weber, B., Spall, H. G. C. V., & Biering‐Sørensen, T. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045770 · Cited by 2
“119 Similarly, a LIRAFLAME (Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes) substudy found that liraglutide reduced coronary inflammation in type 2 diabetes, 120 and a meta-analysis have shown consistent reductions in inflammatory biomarkers across the drug class in diabetes,…”
IDRIS, I. R. (2023) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.74 · Cited by 1
Cellular basis of HFpEF: contributions of abnormal lipids
Chiang, H., Akyol, Ö., Tsai, M., Hochman‐Mendez, C., Elgalad, A., Woodside, D. G., Chen, C., & Bhatt, D. L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1885850 · Cited by 2
“Consequently, intentional weight loss via targeted pharmacological obesity treatment is now a potent, disease-modifying strategy as definitively demonstrated in the recent landmark STEP-HFpEF trial, which investigated the use of semaglutide in obese patients with HFpEF (112).”
D’Elia, E., Limonta, R., Giaccherini, C., Basile, C., Sciatti, E., Zucchetti, O., Odoardo, L. A. F. D., D’Isa, S., Chiesa, E., Gori, M., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf022 · Cited by 2
“9,22,23 Our study population showed a high prevalence of arterial hypertension, diabetes, dyslipidaemia, and obesity—factors that contribute to the inflammatory environment underlying HFpEF.”
Self-citationSemaglutide in non-diabetic patients with Fabry disease
Riccio, E., Capuano, I., & Pisani, A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf088 · Cited by 1
Baidya, D., Kshatri, A. H. S., Zerzan, E. K., Menon, G. J., Sawale, M., & Bhalodiya, S. S. (2026) · Cureus · doi:10.7759/cureus.100590 · Cited by 6
Krasińska, B., Krasiński, Z., & Urbanowicz, T. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114159 · Cited by 2
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Sudden Cardiac Death Risk Stratification in Heart Failure With Preserved Ejection Fraction
Huang, X., Li, Y., Zheng, H., & Xu, Y. C. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000728 · Cited by 2
Abnormal invasive hemodynamics in heart transplant recipients: A single-center, retrospective study
Rajagopalan, N., Dennis, D. R., Akhtarekhavari, J., & Campbell, K. S. (2025) · World Journal of Transplantation · doi:10.5500/wjt.v15.i3.101245 · Cited by 1
Semaglutide: an emerging treatment option for patients with obesity related HFpEF
Khaskheli, S. A., & Rajpar, N. A. (2024) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.20158 · Cited by 1
Desai, A., Sharma, S., Siaw, A., Ruiz, J. R., Gómez, V., & GOSWAMI, R. M. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1579218 · Cited by 1
“Additionally, GLP1 mediated weight loss is also associated with a lower morbidity and functional improvements in 6MWT and quality of life (9).”
A simple tool to screen for heart failure with preserved ejection fraction
Pandey, A., & Zieroth, S. R. (2024) · Nature Medicine · doi:10.1038/s41591-024-03154-9 · Cited by 1
Zhang, Y., Zhao, Z., Kim, S. S.-E., Fabricatore, A. N., & Iyer, P. S. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2535464 · Cited by 4
“Our findings also highlight the suboptimal management of obesity in patients with heart failure, whether HFpEF or HFrEF, as reflected by the low rates of anti-obesity medication use 32 .”
Tsotsios, M., Katsargyris, Α., Moulakakis, K. G., et al. (2026) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2026.03.011 · Cited by 1
Structured Program for Weight Loss in Heart Failure Patients
Rao, V. U., Ziedonis, K., Gunderman, D. J., Kumar, A., Bashall, A., Stark, K., Chugh, A. R., Daly, R. P., & Kalra, A. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100741 · Cited by 2
Noninvasive Screening for Elevated LVEDP and Health Status in Outpatients at Risk for Heart Failure
Cantú-Martínez, O., Girard, A. A., Jin, W., Rinderknecht, D. G., Cheek, T., & Spertus, J. A. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102002 · Cited by 1
Chuang, S., Khetpal, V., Lu, F. Q., & Wu, W. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103304 · Cited by 1
Diastolic Dysfunction in Acute and Critical Illness
Fisher, T., Abbawy, M., Holden, F., Cotton, J. M., Hothi, S. S., Ingram, T. E., Dhamodaran, K., Thilak, S., Chacko, C. J., Gao-Smith, F., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102532 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“In the STEP-HFpEF trial [19] semaglutide 2.4 mg weekly was compared to placebo in 529 participants with obesity and HFpEF.”
InfluentialTreatment of obesity-related HFpEF: a STEP closer to the SUMMIT
Karakasis, P., Fragakis, N., Ruža, I., Stachteas, P., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2477429 · Cited by 2
Divya, A., Dalal, N., Yoshida, Y., Kanwar, M. K., Catarino, P., & DʼAlessandro, D. A. (2026) · ASAIO Journal · doi:10.1097/mat.0000000000002804 · Cited by 1
Sperry, B. W., Carlino, I., & Palazzuoli, A. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10652-0 · Cited by 1
Bruna-Mejías, A., Valenzuela‐Fuenzalida, J. J., Oyanedel-Amaro, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026) · Nutrients · doi:10.3390/nu18111781 · Cited by 3
Tang, H., Zhou, T., Zhang, B., Lu, Y., Kimmel, S. E., Lu, Y., Asch, D. A., & Chen, Y. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.359 · Cited by 2
Troshina, E. A., Suplotova, L. A., Dzgoeva, F. K., Ekusheva, E. V., Vyuchnova, E. S., Okovityi, S. V., Bakulin, I. G., Бакулина, Н. В., Karonova, T. L., Vagapova, G. R., et al. (2026) · Problems of Endocrinology · doi:10.14341/probl13737 · Cited by 1
The diagnosis and subclassification of heart failure with preserved ejection fraction: a review
Creegan, D., Starling, R. C., Hameed, A. G., Daly, M. J., & O’Neill, J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10618-2 · Cited by 2
Müller, M., Schubert, T., Welke, C., Schulz, T. J., Patschkowski, T., Maske, T., Lengenfelder, L. A., Landwehrjohann, L., Donhauser, E., Vogt, E. T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.20.581137 · Cited by 1
Semaglutide Attenuates Neuroinflammation in MicePreprint
Belmont-Rausch, D. M., Ludwig, M. Q., Bentsen, M. A., Hansen, S. N., Secher, A., Holst, D., Moreno, J., Das, V., Egerod, K. L., Bjerregaard, A.-M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.10.698763 · Cited by 1
“…mixed-effects model ± SE are shown. β Regulons are ordered by the difference in values between the LPS-and semaglutide-induced effects, and a full list of differentially activated regulons can be found in Supplementary Tables 8-11. d , Homeostatic gene expression across time and treatment groups.”
InfluentialHuang, Y., Luo, L., Ma, X., Huang, Y., Zhang, C., Hao, X., Zhang, L., Zhu, H., Dai, L., & Liu, M. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047429 · Cited by 1
“82 Although not designed to target immune cells directly, these therapies are associated with improvements in inflammatory burden.”
Medicatie voor obesitas: vooruitgang en uitdagingen
Muskiet, M. H. A., & Boon, M. R. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1569-4 · Cited by 1
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
“The STEP-HFpEF programme 123,124 showed improvements in symptoms, functional status, and exercise capacity in patients with LVEF ≥ 45%.”
Self-citationPropensity Score‐Based Stratified Win Ratio for Augmented Control Designs
Chen, Y., Feng, Y., Sonksen, M., Wang, T., & Song, J. J. (2026) · Statistics in Medicine · doi:10.1002/sim.70487 · Cited by 2
Plutzky, J., Bogdański, P., Colhoun, H. M., Dağdelen, S., Deanfield, J. E., Emerson, S. S., Hovingh, G. K., Kahn, S. E., Ekström, K., Latkovskis, G., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.074482 · Cited by 4
Self-citationPrevention and Management of Heart Failure Associated with Type 2 Diabetics in Rural Australia
Ross, A. G., Mondal, U. K., Mahmood, S., Astawesegn, F. H., Anyasodor, A. E., Huda, M. M., Thapa, S., Aychiluhm, S. B., Giri, S., Rahman, M. F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010304 · Cited by 1
“The STEP-HFpEF trial showed that semaglutide improved functional capacity and quality of life in obese HFpEF patients, although further research is needed before guideline recommendations can be made [68].”
Management of atrial fibrillation in patients with heart failure with preserved ejection fraction
Rambarat, P. K., DeVore, A. D., Mark, D. B., Bahnson, T. D., & Piccini, J. P. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10536-9 · Cited by 1
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 17
Advances in energy balance & metabolism circuitry
Grajales‐Reyes, J. G. (2025) · Advances in genetics · doi:10.1016/bs.adgen.2025.02.003 · Cited by 1
Beyond Blood Pressure: Salt Sensitivity as a Cardiorenal Phenotype—A Narrative Review
Bachlitzanaki, M., Aletras, G., Bachlitzanaki, E., Vasilaki, N., Lydakis, C., Petrakis, I., Foukarakis, E. G., & Stylianou, K. (2026) · Life · doi:10.3390/life16020247 · Cited by 4
“Addressing obesity as a modifiable comorbidity—through structured lifestyle interventions and, when appropriate, pharmacologic strategies—can facilitate BP control, reduce volume burden, and lower long-term cardiovascular risk [105,116,117].”
Review of the top 5 cardiology studies of 2023–24
Barry, A. R., Boswell, R., Babadagli, H. E., Chen, J. W., Cowley, E. C., Eberhardt, T. E., & May, T. A. (2025) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635251339445 · Cited by 1
Yang, Q., Wang, Y., Gao, G., Li, H., Gao, Y., & He, J. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02133-z · Cited by 2
“The results of the STEP-HFpEF trial showed that for obese patients with HFpEF, although treatment with Semaglutide led to a reduction in lean body mass, the 6-minute walk distance was significantly improved [58].”
Heart Failure in Brazil: How Can We Improve its Natural History?
Ferrari, F., Rossi, A. P., & Santander, I. R. M. F. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240644i · Cited by 1
Cardiology: What You May Have Missed in 2025
Atalla, M., Gupta, V., Khalid, M., Kussmaul, W. G., & LaCombe, M. A. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01014 · Cited by 2
Aydın, E., Durdu, H., Vural, A., Yildirim, C., Kurt, D., Bayramlı, U., & Gök, G. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05833-6 · Cited by 1
“…that the functional decline in HFpEF is not merely a consequence of generalized obesity but is specifically driven by the synergistic burden of visceral cardiac adiposity (high EAT) and skeletal muscle oxidative metabolism and mitochondrial efficiency failure (low muscle endurance) [11, 12].”
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
Fernandez, M. L. O., Torrigiani, G., Molteni, M., Fortino, I., Cimminiello, C., & Baviera, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02674-9 · Cited by 3
“GLP1-RAs could ameliorate HFpEF, as shown in two recent trials [11, 12], but their role in HFrEF is more ambiguous [10].”
Katsura, M., Horiuchi, Y., Tanabe, K., & Wettersten, N. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70721 · Cited by 1
“In the STEP-HFpEF trial, semaglutide improved quality of life and functional status, and reduced body weight in obese patients with established HFpEF [12].”
Tatekoshi, Y., Chen, C., Shapiro, J. S., Chang, H., Blancard, M., Lyra‐Leite, D. M., Burridge, P. W., Feinstein, M. J., D’Aquila, R. T., Hsue, P. Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.575991 · Cited by 1
Goldenberg, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15588 · Cited by 3
Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches
DeFilippis, E. M., Cheng, R. K.-H., DONALD, E. M., Dunlay, S. M., Evangelista, L. S., Kamdar, F. D., Khazanie, P., Mohammed, S. F., Rossi, A., Spall, H. G. C. V., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013747 · Cited by 1
Guedouari, H., Dia, M., Geoffray, J., Brun, C., Moulin, F., Givre, L., Belmudes, L., Léon, C., Chanon, S., Ji-Cao, J., et al. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100453 · Cited by 5
The changing landscape of heart failure: translating management into the modern era
Madaudo, C., Ibrahim, W., Noakes, D., Bromage, D. I., Sinagra, G., McDonagh, T., & Cannata, A. N. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106633 · Cited by 1
Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders
Grave, R. D. (2024) · IJEDO · doi:10.32044/ijedo.2024.02 · Cited by 1
Mondellini, G. M., Heemann, J., Galloo, X., Plein, D., Soens, L., Borlaug, B. A., Guazzi, M., & Verbrugge, F. H. (2026) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2026.2721796 · Cited by 2
Self-citationEisa, N., & Barood, O. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.04.014 · Cited by 2
Gouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
Self-citationRodríguez, J. M. F., Ortiz, M. B. A., Cerrada, J. C., Chivite, D., Romano, P. C., Alonso, R. G., Almorós, A. L., Miramontes‐González, J. P., Rangel, L. S., & Pérez-Silvestre, J. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502471 · Cited by 1
Heart Failure with Preserved Ejection Fraction in the Indian Context
Gupta, R., Choudhary, M., & Guptha, S. (2025) · Journal of Indian College of Cardiology · doi:10.4103/jicc.jicc_65_24 · Cited by 1
Alshammari, B., Alanazi, L., Dardouri, M., Aouicha, W., Tlili, M. A., Alkubati, S. A., Alrasheeday, A., Almuaiqli, A. M., Alqahtani, A. S., Alanazi, M. S., et al. (2025) · Healthcare · doi:10.3390/healthcare13050522 · Cited by 3
“HF is characterized by the heart’s inability to adequately supply blood to meet the body’s needs, which significantly diminishes patients’ quality of life and places a heavy strain on healthcare systems [2,3].”
Gestion périopératoire des nouveaux traitements médicamenteux de l’insuffisance cardiaque
Delignette, M., Chaffard, C., Orion, M., & Blet, A. (2024) · Le Praticien en Anesthésie Réanimation · doi:10.1016/j.pratan.2024.09.003 · Cited by 1
Pedicino, D., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf277 · Cited by 1
Obesity in Cardiorenal syndrome: Management Opportunities and Challenges
Reaves, A. C., Jaffe, E., & McCallum, W. I. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01352-5 · Cited by 1
“[41] The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial was unique in that it examined primary CV outcomes in non-diabetic patients with overweight and obesity (BMI ≥ 27 kg/ m 2 ).”
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Vignarajah, A., Oro, P., Dahdah, J. E., Vigneswaramoorthy, N. A., Vest, A. R., & Shah, G. V. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100676 · Cited by 5
“The STEP-HFpEF trial demonstrated that semaglutide significantly improved functional status including better symptoms, quality of life, and exercise capacity in obese patients with heart failure with preserved ejection fraction, although it did not examine the clinical outcomes [4].”
Maki, K. C., & Duell, P. B. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.008 · Cited by 1
Alper, A., Fagin, A., Karthikeyan, A., Karp, A., Terashima, R., Murli, H., Gershon, A., & FAILLACE, R. T. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00814-4 · Cited by 1
Estler, B., Fröhlich, H., Täger, T., Frey, N., & Frankenstein, L. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01621-4 · Cited by 1
“In the more restrictive scenario, we approximated real-world eligibility by applying the ratio of randomized to screened participants in STEP-HFpEF (529/817, corresponding to an eligibility fraction of approximately 0.647) to the HFpEF + obesity population [9].”
InfluentialLiuzzo, G., Greene, S. J., Mendieta, G., & Fordyce, C. B. (2026) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2026.06.001 · Cited by 2
SURPASS ‐ CVOT and the Emerging Biology of Cardiometabolic Benefit
Corrao, S., Cosentino, F., & Federici, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71175 · Cited by 1
GLP-1 receptor agonists and heart failure: insights from human genetics
Emanuelsson, F., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1058 · Cited by 1
Pagnesi, M., Riccardi, M., Maisano, F., Antohi, E., Barberis, V. I., Hamid, M. A., Arfsten, H., Grapsa, J., Karam, N., Muraru, D., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf027 · Cited by 1
Cardiovascular effects of semaglutide: Multifaceted mechanisms of systemic organoprotection
Demidova, T. Y., Izmaylova, M. Y., & Alieva, M. A. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-06 · Cited by 1
Tipping the Scales: Strategies to Improve Anti‐Obesity Medication Access and Affordability
Komé, A. M., Boykin, A. R., Johnson-Jennings, A., & Coviello, A. D. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70118 · Cited by 1
“[10], STEP-HFpEF [11], SURMOUNT-OSA [12]), and risk of disease progression if AOM therapy is withheld.”
Rate-adaptive pacing in heart failure with preserved ejection fraction: Too much of a good thing?
Oraii, A., Chaumont, C., Marchlinski, F. E., & Hyman, M. C. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.03.010 · Cited by 2
“20,21 – 23 Other examples of therapies targeting individual pathobiological responses in HFpEF have been less successful.”
Background吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity
Gupta, R., & Sharma, S. (2025) · Current Signal Transduction Therapy · doi:10.2174/0115743624346660250317013032 · Cited by 2
Hasebe, M., Kamido, H., Su, C., Keidai, Y., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70749 · Cited by 2
Sriram, S., & Arnolda, L. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261448034 · Cited by 1
“69,70 These benefits were observed despite only modest weight reduction within the trial population, with participants achieving a mean loss of approximately 9.8 kg during the first year of treatment.”
InfluentialKokura, Y., Kishimori, T., Kato, T., Iwasaki, Y., Wada, A., Tani, A., Yamaji, R., Koike, J., Matsumoto, T., Yagi, T., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113404 · Cited by 1
Herrmann, E. J., Lange, D., Hannig, J., Zimmer, G., Grün, D., Keller, T., Edegran, A., Johnson, L., Sossalla, S. T., Guckert, M., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02564-6 · Cited by 1
HFpEF Without Obesity: Fallen Off the Radar?
Nelson, A. J., & Pagidipati, N. J. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.011 · Cited by 1
What's new in pharmacotherapy at ESC Congress 2023?
Gragnano, F., Calabrò, P., & Galli, M. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad064 · Cited by 1
Marzano, F., Paolillo, S., Gargiulo, P., Cotticelli, C., Santo, M. D., Nardi, E., Abbellito, G. M., Liccardi, L., Filardi, F. P., Bruzzese, D., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03215-y · Cited by 4
“…receptor agonists, semaglutide was the only agent studied in multiple clinical settings, including diabetic patients with atherosclerotic CV disease [7], chronic kidney disease [8], peripheral artery disease [9], non-diabetic patients with obesity [5] and HF patients with and without T2DM [10, 11].”
KOVIL, R. R., Shah, T., Tanna, S., Negalur, V. B., PATANGE, S. A., Sanghvi, A., Manoria, P., TIWASKAR, M. H., PADHYE, D. A., Sowani, A., et al. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_22_25 · Cited by 2
Self-citationCornelio, C. K., Cowart, K., Perkins, J. B., Alomar, M., Pineda-Gayoso, R., Miranda, A. C., Phan, A. T., & White, R. T. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70130 · Cited by 5
“In addition to the demonstrated reduction in CV events and renal outcomes among people with T2D, emerging randomized trial evidence for benefits in HF with preserved ejection fraction is becoming more recognized [16, 21].”
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Dhont, S., Meekers, E. M., Müllens, W., Pison, L., Bertrand, P. B., Tang, W. H. W., & Martens, P. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.04.001 · Cited by 1
Su, W., Wang, X., Wang, Q., Pei, J., & Fang, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323634 · Cited by 1
Obésité et insuffisance cardiaque
Isnard, R., Legrand, L., & Pousset, F. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.12.008 · Cited by 1
Acute cardiovascular care 2024 in review: acute heart failure
Platz, E., Aleksić, M., & Verbrugge, F. H. (2024) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuae145 · Cited by 1
Wolf, P. J. W., Correia, E. B., Neto, J. M. R., Finger, M. A., dos Santos, C. C., de Vasconcellos, M. A. B., Bruscky, L. V. R., Murta, A. C. D. S., Francisco, Y. A., Albrecht, F. C., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240676i · Cited by 1
“In fact, when it comes to the effects of MRAs (acting to reduce congestion, sodium retention, endothelial dysfunction, inflammation, fibrosis, and hypertrophy), 23 the positive consequences of this mineralocorticoid antagonist in HFpEF seem to be justifiable, especially given its action on several specific pathophysio…”
InfluentialGlucagon-Like Peptide-1 Agonist Effects on Weight Loss and Heart Failure Hemodynamics
Alvarado, A., Martinez-Ponce, J., Ubysz, O., Costa, A., Ataya, L., & Brancheau, D. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.110528 · Cited by 1
A contemporary review on heart failure with improved ejection fraction
Weiss, A., Flowers, A., Eisenberg, S. D., Wu, L., Rodríguez, M. R., Khawaja, M., Moras, E., Lavie, C. J., Fonarow, G. C., Tang, W. H. W., et al. (2025) · npj Cardiovascular Health · doi:10.1038/s44325-025-00093-3 · Cited by 6
“…points; 95% CI: 4.8 – 10.9; P < 0.001), a reduction in mean body weight (estimated difference: − 10.7 percentage points; 95% CI: − 11.9 to − 9.4; P < 0.001), and improved exercise capacity, as assessed by the 6-minute walk test (estimated difference: 20.3 m; 95% CI: 8.6 – 32.1; P < 0.001) 75,76 .”
InfluentialLi, Q., Zhu, Y., Zhao, Y., Danzeng, C., Wang, D., Jiang, R., Chen, F., Lin, X., Hu, L., & Wang, Y. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112315 · Cited by 2
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF
Kamat, I., & Nair, A. P. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012432 · Cited by 1
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.